geqopimozaqyxyh.blogspot.com
Hematide is in a Phase III trial. Rentob led Onyx for nearly 15 years, stepping down in Februarh 2008as president, CEO, chairman and a memberr of Onyx’s board. At the company, he helped negotiated a research, development and commercializatiob partnership with that resulted inthe anti-cancer drug Nexavar tablets, which cost aboug $5,000 a month in the United States and are approaching $1 billiom in annual sales, are approved in more than 80 countries to treayt kidney cancer and 70-plus countries for liver Prior to joining Onyx, Renton was president and COO of which acquired Cetus in 1991. Renton had been president of Cetussincee 1990, COO since 1987 and CFO from 1983 to 1987.
Rento also serves on the boardsof , Cepheid and the Speciapl Olympics of Northern California.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment